These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 35246670)

  • 1. Inflammation and immune dysfunction in Parkinson disease.
    Tansey MG; Wallings RL; Houser MC; Herrick MK; Keating CE; Joers V
    Nat Rev Immunol; 2022 Nov; 22(11):657-673. PubMed ID: 35246670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson's Disease?
    Koukoulis TF; Beauchamp LC; Kaparakis-Liaskos M; McQuade RM; Purnianto A; Finkelstein DI; Barnham KJ; Vella LJ
    J Parkinsons Dis; 2024; 14(2):227-244. PubMed ID: 38427502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson's Disease.
    Al-Nusaif M; Lin Y; Li T; Cheng C; Le W
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
    Caputi V; Giron MC
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease.
    Zhu M; Liu X; Ye Y; Yan X; Cheng Y; Zhao L; Chen F; Ling Z
    Front Immunol; 2022; 13():937555. PubMed ID: 35812394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation in Parkinson's Disease: Triggers, Mechanisms, and Immunotherapies.
    Wang T; Shi C; Luo H; Zheng H; Fan L; Tang M; Su Y; Yang J; Mao C; Xu Y
    Neuroscientist; 2022 Aug; 28(4):364-381. PubMed ID: 33576313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop.
    Arena G; Sharma K; Agyeah G; Krüger R; Grünewald A; Fitzgerald JC
    Curr Neurol Neurosci Rep; 2022 Aug; 22(8):427-440. PubMed ID: 35674870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking Parkinson Disease: Exploring Gut-Brain Interactions and the Potential Role of Exercise.
    Zapanta K; Schroeder ET; Fisher BE
    Phys Ther; 2022 May; 102(5):. PubMed ID: 35225349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy.
    Nohesara S; Abdolmaleky HM; Thiagalingam S; Zhou JR
    Epigenomics; 2024 Jan; 16(1):57-77. PubMed ID: 38088063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.
    Dogra N; Mani RJ; Katare DP
    Cell Mol Neurobiol; 2022 Mar; 42(2):315-332. PubMed ID: 33649989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities.
    Araújo B; Caridade-Silva R; Soares-Guedes C; Martins-Macedo J; Gomes ED; Monteiro S; Teixeira FG
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease.
    Kaur G; Behl T; Bungau S; Kumar A; Uddin MS; Mehta V; Zengin G; Mathew B; Shah MA; Arora S
    Curr Neuropharmacol; 2021; 19(2):233-247. PubMed ID: 32504503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance.
    Bi M; Feng L; He J; Liu C; Wang Y; Jiang H; Liu SJ
    Ageing Res Rev; 2022 Dec; 82():101759. PubMed ID: 36243356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment.
    Varesi A; Campagnoli LIM; Fahmideh F; Pierella E; Romeo M; Ricevuti G; Nicoletta M; Chirumbolo S; Pascale A
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease.
    Kip E; Parr-Brownlie LC
    Ageing Res Rev; 2022 Jun; 78():101618. PubMed ID: 35395416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis.
    Claudino Dos Santos JC; Lima MPP; Brito GAC; Viana GSB
    Ageing Res Rev; 2023 Feb; 84():101812. PubMed ID: 36455790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.